1. Home
  2. IMCR vs PEB Comparison

IMCR vs PEB Comparison

Compare IMCR & PEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immunocore Holdings plc

IMCR

Immunocore Holdings plc

HOLD

Current Price

$28.63

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Logo Pebblebrook Hotel Trust of Beneficial Interest

PEB

Pebblebrook Hotel Trust of Beneficial Interest

HOLD

Current Price

$15.55

Market Cap

1.7B

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMCR
PEB
Founded
2008
2009
Country
United Kingdom
United States
Employees
N/A
52
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.7B
IPO Year
2016
N/A

Fundamental Metrics

Financial Performance
Metric
IMCR
PEB
Price
$28.63
$15.55
Analyst Decision
Buy
Hold
Analyst Count
10
11
Target Price
$66.33
$13.30
AVG Volume (30 Days)
304.3K
2.2M
Earning Date
05-07-2026
04-28-2026
Dividend Yield
N/A
0.28%
EPS Growth
30.39
N/A
EPS
0.25
N/A
Revenue
$249,428,000.00
N/A
Revenue This Year
$14.57
N/A
Revenue Next Year
$8.21
$2.25
P/E Ratio
$117.72
N/A
Revenue Growth
43.05
N/A
52 Week Low
$27.56
$8.80
52 Week High
$40.71
$15.16

Technical Indicators

Market Signals
Indicator
IMCR
PEB
Relative Strength Index (RSI) 44.87 70.95
Support Level $27.69 $13.77
Resistance Level $31.56 N/A
Average True Range (ATR) 1.14 0.37
MACD 0.08 0.06
Stochastic Oscillator 22.02 93.20

Price Performance

Historical Comparison
IMCR
PEB

About IMCR Immunocore Holdings plc

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.

About PEB Pebblebrook Hotel Trust of Beneficial Interest

Pebblebrook Hotel Trust currently owns upper upscale and luxury hotels with 11,052 rooms across 44 hotels in the United States. Pebblebrook acquired LaSalle Hotel Properties, which owned 10,451 rooms across 41 US hotels, in November 2018, though management has sold many of those hotels over the past few years. Pebblebrook's portfolio consists mostly of independent hotels with no brand affiliations, though the combined company does own and operate some hotels under Marriott, Starwood, InterContinental, Hilton, and Hyatt brands.

Share on Social Networks: